Pre-exposure prophylaxis ( PrEP ) trials using tenofovir-based regimens have demonstrated that high levels of adherence are required to evaluate efficacy ; the incorporation of objective biomarkers of adherence in trial design has been essential to interpretation , given the inaccuracy of self-report .